Roth Capital analysts are weighing in on solar-system company SolarCity Corp (NASDAQ:SCTY) and biotech company ContraFect Corp (NASDAQ:CFRX), as news of a potential investment tax credit extension and Phase 1 …
In a research report issued yesterday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on ContraFect Corp. (NASDAQ:CFRX) with a price target …
